How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: NNC0487-0111 (drug), Placebo (matched to NNC0487-0111) (drug)
How long the study runs: Study runs about 27 months (dates as stated)
About the drug or intervention: NNC0487-0111 — drug: NNC0487-0111 will be administered subcutaneously. · Placebo (matched to NNC0487-0111) — drug: Placebo will be administered subcutaneously.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 606
Started: 2026-04-21
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for obesity
• Phase3 - 606 participants
• The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight

Who can take part?

• Ages 18 Years and over
• Diagnosed with obesity

Where?

• Macclesfield - EMS Healthcare
• Rotherham - Clifton Medical Centre
• Soham - Staploe Medical Centre
• Wellingborough - Albany House Medical Centre

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Obesity

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

What the study is looking for

✓Male or female (sex at birth).
✓Age 18 years or above at the time of signing the agreement to take part.

Who cannot take part

✗Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by...
✗History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
✗Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP 1/gastric inhibitory peptide (GIP)...

See the full criteria

Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. Exclusion Criteria: * Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records. * Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP 1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.

Where Is This Study? (4 UK sites)

EMS Healthcare

Macclesfield SK10 4TF, United Kingdom

Clifton Medical Centre

Rotherham S65 1DA, United Kingdom

Staploe Medical Centre

Soham CB7 5JD, United Kingdom

Albany House Medical Centre

Wellingborough NN8 4RW, United Kingdom

Data sourced from ClinicalTrials.gov · Last verified: 2026-09